Cosmo Pharmaceuticals N.V. Stock

Equities

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:06 2024-06-14 EDT 5-day change 1st Jan Change
72.1 CHF -0.55% Intraday chart for Cosmo Pharmaceuticals N.V. -3.61% +41.65%

Financials

Sales 2024 * 264M 282M 251M 387M Sales 2025 * 242M 259M 230M 355M Capitalization 1.21B 1.3B 1.16B 1.78B
Net income 2024 * 124M 133M 118M 182M Net income 2025 * 76M 81.34M 72.4M 112M EV / Sales 2024 * 4.15 x
Net cash position 2024 * 120M 128M 114M 176M Net cash position 2025 * 210M 225M 200M 309M EV / Sales 2025 * 4.15 x
P/E ratio 2024 *
9.87 x
P/E ratio 2025 *
13.3 x
Employees 325
Yield 2024 *
2.78%
Yield 2025 *
1.02%
Free-Float 44.36%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Cosmo Pharmaceuticals N.V.

1 day-0.55%
1 week-3.61%
Current month+1.84%
1 month+0.14%
3 months+6.50%
6 months+35.02%
Current year+41.65%
More quotes
1 week
71.80
Extreme 71.8
75.70
1 month
69.40
Extreme 69.4
75.70
Current year
51.20
Extreme 51.2
76.00
1 year
33.70
Extreme 33.7
76.00
3 years
33.70
Extreme 33.7
90.10
5 years
33.70
Extreme 33.7
99.80
10 years
33.70
Extreme 33.7
193.70
More quotes
Managers TitleAgeSince
Director of Finance/CFO 52 16-05-31
Chairman 61 05-12-31
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 96-12-31
Director/Board Member 69 12-03-31
Chairman 61 05-12-31
More insiders
Date Price Change Volume
24-06-14 72.1 -0.55% 6,741
24-06-13 72.5 -2.42% 17,077
24-06-12 74.3 +0.81% 8,535
24-06-11 73.7 -1.60% 15,524
24-06-10 74.9 +0.13% 13,811

Delayed Quote Swiss Exchange, June 14, 2024 at 11:30 am

More quotes
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
75.63 EUR
Average target price
96.19 EUR
Spread / Average Target
+27.18%
Consensus